← All trials
NCT06890715
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 24, 2024
- Primary completion
- Jul 2, 2024
- Completion date
- Jul 8, 2024
- First posted
- Mar 24, 2025
- Last posted
- Mar 24, 2025
- Enrollment
- 12
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Overseas Pharmaceuticals, Ltd.Lead sponsor
- Beijing CTSmed Co. LtdCollaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.